Myint, K.Z.; Balasubramanian, B.; Venkatraman, S.; Phimsen, S.; Sripramote, S.; Jantra, J.; Choeiphuk, C.; Mingphruedhi, S.; Muangkaew, P.; Rungsakulkij, N.;
et al. Therapeutic Implications of Ceritinib in Cholangiocarcinoma beyond ALK Expression and Mutation. Pharmaceuticals 2024, 17, 197.
https://doi.org/10.3390/ph17020197
AMA Style
Myint KZ, Balasubramanian B, Venkatraman S, Phimsen S, Sripramote S, Jantra J, Choeiphuk C, Mingphruedhi S, Muangkaew P, Rungsakulkij N,
et al. Therapeutic Implications of Ceritinib in Cholangiocarcinoma beyond ALK Expression and Mutation. Pharmaceuticals. 2024; 17(2):197.
https://doi.org/10.3390/ph17020197
Chicago/Turabian Style
Myint, Kyaw Zwar, Brinda Balasubramanian, Simran Venkatraman, Suchada Phimsen, Supisara Sripramote, Jeranan Jantra, Chaiwat Choeiphuk, Somkit Mingphruedhi, Paramin Muangkaew, Narongsak Rungsakulkij,
and et al. 2024. "Therapeutic Implications of Ceritinib in Cholangiocarcinoma beyond ALK Expression and Mutation" Pharmaceuticals 17, no. 2: 197.
https://doi.org/10.3390/ph17020197
APA Style
Myint, K. Z., Balasubramanian, B., Venkatraman, S., Phimsen, S., Sripramote, S., Jantra, J., Choeiphuk, C., Mingphruedhi, S., Muangkaew, P., Rungsakulkij, N., Tangtawee, P., Suragul, W., Farquharson, W. V., Wongprasert, K., Chutipongtanate, S., Sanvarinda, P., Ponpuak, M., Poungvarin, N., Janvilisri, T.,
... Tohtong, R.
(2024). Therapeutic Implications of Ceritinib in Cholangiocarcinoma beyond ALK Expression and Mutation. Pharmaceuticals, 17(2), 197.
https://doi.org/10.3390/ph17020197
